RCAMU
INSY

Rothschild & Co Asset Management US’s Insys Therapeutics, Inc. INSY Stock Holding History

Rothschild & Co Asset Management US’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-436,775
Closed -$6.98M – 589
2016
Q1 		$6.98M Buy
436,775
+11,548
+3% +$219K 0.13% 230
2015
Q4 		$12.2M Buy
425,227
+22,259
+6% +$617K 0.22% 152
2015
Q3 		$11.5M Buy
402,968
+58,572
+17% +$2.16M 0.22% 155
2015
Q2 		$12.4M Buy
344,396
+8,330
+2% +$259K 0.23% 151
2015
Q1 		$9.77M Buy
336,066
+6,446
+2% +$170K 0.19% 189
2014
Q4 		$6.95M Sell
329,620
-8,688
-3% -$172K 0.14% 218
2014
Q3 		$6.56M Sell
338,308
-13,630
-4% -$214K 0.14% 221
2014
Q2 		$5.5M Sell
351,938
-2,172
-0.6% -$35.1K 0.11% 268
2014
Q1 		$7.33M Sell
354,110
-13,558
-4% -$269K 0.16% 221
2013
Q4 		$4.74M Buy
+367,668
New +$5.1M 0.11% 278

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rothschild & Co Asset Management US's INSY Position: Q2 2016 in Review

Rothschild & Co Asset Management US sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 436,775 shares — an estimated $6.98M sold.

Rothschild & Co Asset Management US first reported a position in INSY in Q4 2013 and held it in 10 quarters. The position peaked at $12.4M in Q2 2015. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

  • Rothschild & Co Asset Management US reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 436,775 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $6.98M.
  • Rothschild & Co Asset Management US first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 10 quarters.
  • Rothschild & Co Asset Management US's Insys Therapeutics, Inc. position peaked at $12.4M in Q2 2015.
  • 124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Rothschild & Co Asset Management US's 13F filing for Q2 2016, filed 3 Aug 2016.